Melanoma (Advanced & Metastatic)
Melanoma has been transformed by BRAF-targeted therapy and immune checkpoint inhibitors, with combination nivolumab-ipilimumab achieving durable responses in a subset of metastatic patients. BRAF V600 mutation status, tumor mutational burden, and LDH are key prognostic and predictive factors. CancerFax helps patients with advanced or refractory melanoma access BRAF-MEK combinations, novel IO strategies, and clinical trials.
- BRAF V600, TMB & melanoma molecular profiling
- BRAF-MEK combo, dual checkpoint & TIL therapy
- Advanced melanoma specialist & clinical trial access
- Key Test
- Biopsy · Imaging · Molecular Panel
- Advanced Therapies
- Targeted Therapy · Immunotherapy
- Critical Factor
- Molecular profile · Stage at diagnosis
What is Melanoma
Types and Subtypes
Understanding the specific type and molecular subtype of melanoma is essential for determining the most appropriate treatment approach.
Symptoms and Signs
Symptoms of melanoma vary by stage and tumor location. Early-stage disease may be asymptomatic or cause only subtle symptoms.
Diagnosis and Staging
Definitive diagnosis requires tissue biopsy and comprehensive staging imaging. Molecular testing is essential for treatment planning.
Staging
Staging determines treatment intent and guides therapeutic decision-making.
Standard Treatment
Treatment is determined by histologic type, stage, molecular profile, and performance status.
Advanced & Emerging Therapies
The treatment landscape for advanced melanoma continues to evolve with new targeted agents and immunotherapy combinations.
Immunotherapy
Checkpoint Inhibitors
Pembrolizumab and nivolumab-based regimens have transformed recurrent/metastatic disease in eligible patients based on PD-L1 expression and molecular profile.
Targeted Therapy
Molecular-Guided Targeted Agents
Specific targeted agents are available for molecularly defined subgroups. Comprehensive NGS at diagnosis identifies eligible patients.
Biomarkers & Precision Medicine
Molecular biomarker testing is increasingly important for treatment selection in advanced disease.
When to Seek a Second Opinion
Specialist review is valuable at key decision points in management.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis is stage- and molecular profile-dependent.
Supportive Care
Supportive care is integral to maintaining quality of life throughout treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax supports melanoma patients by reviewing pathology, BRAF mutation status, PD-L1 expression, and staging; coordinating specialist melanoma oncology second opinions; facilitating access to BRAF/MEK inhibitor combinations, pembrolizumab, nivolumab + ipilimumab, and clinical trials; and supporting patients exploring specialist melanoma treatment globally.
Get a free case reviewFrequently Asked Questions
Melanoma arises from melanocytes — the pigment-producing cells of the skin. While it accounts for only ~1% of skin cancers, it causes the large majority of skin cancer deaths due to its propensity for early metastasis. Cutaneous melanoma is the most common form; rarer subtypes include acral lentiginous melanoma (arising on palms, soles, and nail beds — more common in Asian and African populations), mucosal melanoma (arising in oral, nasal, anal, or genitourinary mucosa), and uveal (ocular) melan... Treatment depends on stage and molecular profile. Contact CancerFax for specialist guidance.
A specialist second opinion is valuable when the diagnosis is complex, when molecular testing reveals actionable alterations, when treatment planning involves complex surgical or radiation decisions, or when disease has progressed and next-line options are being considered. Specialist centers may offer clinical trial access and treatment options not available locally.
Yes. CancerFax can assist by reviewing your medical reports, coordinating specialist second opinions, confirming molecular eligibility for targeted therapies and immunotherapy, and facilitating access to specialist centers and clinical trials globally including in China. Contact CancerFax to discuss your diagnosis and available options.